Acadia Pharmaceuticals (ACAD) Cost of Revenue (2016 - 2026)

Acadia Pharmaceuticals' Cost of Revenue history runs 11 years deep, the most recent figure standing at $24.8 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 21.57% year-over-year to $24.8 million in Q1 2026; TTM through Mar 2026 was $93.4 million, a 17.8% increase from a year earlier, with the FY2025 full-year figure at $89.0 million, up 8.75% from the prior year.
• Cost of Revenue fell to $24.8 million in Q1 2026 per ACAD's latest filing, from $26.2 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $26.2 million in Q4 2025 and bottomed at $1.7 million in Q1 2023.
• The 5-year median for Cost of Revenue is $18.2 million (2024), against an average of $14.6 million.
• Across the five-year window, Cost of Revenue tumbled 77.54% in 2022 and jumped 1276.78% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $2.4 million in 2022, then jumped by 641.44% to $17.9 million in 2023, then climbed by 21.87% to $21.8 million in 2024, then advanced by 20.28% to $26.2 million in 2025, then declined by 5.47% to $24.8 million in 2026.
• Per Business Quant, the three latest ACAD Cost of Revenue figures stand at $24.8 million (Q1 2026), $26.2 million (Q4 2025), and $21.6 million (Q3 2025).